Lung Cancer

Second-line treatment with sacituzumab govitecan-hziy led to responses in patients with extensive-stage small cell lung cancer, according to results from the phase 2 TROPiCS-03 trial.

Dostarlimab plus chemotherapy elicited a higher objective response rate and showcased a numerical improvement in overall survival compared with pembrolizumab and chemotherapy in patients with treatment-naïve, nonsquamous non–small cell lung cancer.

Concurrent adagrasib and pembrolizumab generated early signals of efficacy in patients with treatment-naïve, advanced non–small cell lung cancer harboring KRAS G12C mutations, particularly in those who had a PD-L1 tumor proportion score of at least 50%.

Treatment with the bispecific T-cell engager tarlatamab demonstrated antitumor activity and favorable safety outcomes in patients with previously treated small cell lung cancer.

Specialists in breast cancer review toxicity management practices for T-DM1 and trastuzumab deruxtecan [T-DXd].

A breast medical oncologist provides insights on antibody-drug conjugates in the breast cancer space and discusses ongoing research.

The 2023 ESMO Congress, which is taking place in Madrid, Spain, and will continue to be accessible online via a virtual platform, is gearing up to kick off, and the oncology community is ready to learn more about the latest data across malignancies.

David S. Hong, MD, and David Sommerhalder, MD, discuss the unmet needs for patients with KRAS G12C–mutant non–small cell lung cancer (NSCLC) and colorectal cancer (CRC) that prompted the initiation of the RMC-6291-001 trial; the key efficacy and safety findings with RMC-6291 in patients with NSCLC and CRC; and potential next steps for this agent.

Expert perspectives on unmet needs and therapies available for patients with EGFR-mutated non–small cell lung cancer.

Ticiana Leal, MD, gives a comprehensive overview of treatment options for patients with EGFR-mutated NSCLC who progress on osimertinib therapy.

Wade T. Iams, MD, discusses the impact of adagrasib on the treatment of patients with KRAS G12C-mutant NSCLC in the second line, as well as its integration into clinical practice.

David S. Hong, MD, discusses preliminary efficacy data from a phase 1 trial f the KRAS G12C inhibitor RMC-6291 in advanced KRAS G12C–mutant solid tumors.

Expression of DLL3, an inhibitor ligand of the Notch pathway associated with tumorigenesis, has emerged as a target of interest for drug development.

The FDA has approved pembrolizumab (Keytruda) in combination with platinum-containing chemotherapy as neoadjuvant treatment, and with continuation of pembrolizumab monotherapy as post-surgical adjuvant treatment for patients with resectable non–small cell lung cancer.

Omar Abughanimeh, MD, discusses the evolution of targeted therapies for patients with EGFR-positive non-small cell lung cancer.

Joachim G. J. V. Aerts, MD, PhD, discusses how dendritic cell vaccines could bolster historically poor responses to immunotherapy in patients with mesothelioma, reports and provides potential explanations for negative results from the DENIM trial, and details a potential role for this therapy in earlier lines of mesothelioma treatment.

The FDA has granted priority review to the supplemental new drug application seeking the approval of osimertinib in combination with chemotherapy for the treatment of patients with EGFR-mutated locally advanced or metastatic non–small cell lung cancer.

The European Commission has approved pembrolizumab as adjuvant monotherapy for the treatment of adult patients with non–small cell lung cancer who are at high risk of recurrence following complete resection and platinum-based chemotherapy.

Treatment with the combination of ceralasertib and durvalumab elicited preliminary efficacy signals in patients with advanced non–small cell lung cancer with and without RAS mutations who received prior treatment with immune checkpoint blockade.

The expert panel has a comprehensive discussion about best practices for patient education and the barriers to effective testing.

Medical oncologists review the complexities of molecular testing, including tissue exhaustion, and discuss management approaches.

Vinai Gondi, MD, discusses efficacy and safety findings from the phase 2/3 NRG-CC003 trial of prophylactic cranial irradiation in patients with small cell lung cancer.

Treatment with the novel, ALK-selective TKI NVL-655 generated responses and was well tolerated in heavily pretreated patients with ALK-positive, advanced non–small cell lung cancer.

The FDA has approved FoundationOne® CDx and FoundationOne Liquid CDx for use as companion diagnostics to identify patients with metastatic non–small cell lung cancer harboring BRAF V600E mutations who may benefit from treatment with the combination of encorafenib plus binimetinib.

Ravi Salgia, MD, PhD, discusses the 2023 Bridging the Gaps in Lung Cancer meeting, highlighting unmet needs that remain regarding treatment-related toxicities that can arise with commonly used agents in patients with lung cancer.